Literature DB >> 17679948

Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.

Martin Weger1, Wilfried Renner, Iris Steinbrugger, Katharina Köfer, Andreas Wedrich, Andrea Groselj-Strele, Yosuf El-Shabrawi, Otto Schmut, Anton Haas.   

Abstract

PURPOSE: Exudative age-related macular degeneration (AMD) is one of the most common causes of severe visual loss. Both environmental and genetic factors, such as the complement factor H (CFH) 402H allele, have been associated with AMD. Recently, the HTRA1 -625A allele was identified as a novel risk marker in both a North American and a Chinese population. The present study was performed to evaluate the association of the HTRA1 -625A allele with exudative AMD in a Central European population.
METHODS: The present case-control study included 242 patients with exudative AMD and 157 control subjects. Genotypes of the HTRA1 -625G>A polymorphism were determined by a 5'-exonuclease assay (TaqMan). Determination of CFH Y402H genotypes was done by allele specific digestion of polymerase chain products.
RESULTS: Carriers of the HTRA1 -625AA genotype were found significantly more often in AMD patients than among control subjects (27.7% versus 5.1%; p<0.001). Binary logistic regression analysis binary logistic regression analysis revealed an odds ratio (OR) of 2.7 (95% confidence interval (CI): 1.1-6.8) for AMD among subjects heterozygous for the HTRA1 -625A allele compared to those with the wildtype genotype, when adjusted for CFH Y402H genotypes (p=0.034). The OR increased to 10.2 (95% CI: 3.0-34.5) among subjects homozygous for the HTRA1 -625A allele (p<0.001). The OR for AMD among heterozygous carriers of the CFH 402H variant was 3.6 (95% CI: 1.6-7.8) compared to those with the wildtype genotype, when adjusted for HTRA1 -625G>A genotypes (p=0.001). The OR increased to 9.8 (95% CI: 3.7-25.9) among subjects homozygous for the CFH 402HH genotype (p<0.001). Interaction terms between CFH and HTRA1 genotypes were not significantly associated with AMD.
CONCLUSIONS: Our data suggest that both the HTRA1 -625A allele and the CFH 402H allele are independently associated with exudative AMD in a Central European population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17679948

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  18 in total

Review 1.  LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.

Authors:  Yu Tong; Jing Liao; Yuan Zhang; Jing Zhou; Hengyu Zhang; Meng Mao
Journal:  Mol Vis       Date:  2010-10-05       Impact factor: 2.367

Review 2.  The molecular genetic basis of age-related macular degeneration: an overview.

Authors:  Saritha Katta; Inderjeet Kaur; Subhabrata Chakrabarti
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

3.  Association of Htra1 gene polymorphisms with the risk of developing AMD in Iranian population.

Authors:  Mohammad Askari; Amin Reza Nikpoor; Fazel Gorjipour; Mohsen Mazidi; Mohammad Hosein Sanati; Hajar Aryan; Alireza Irani; Khalil Ghasemi Falavarjani; Hossein Nazari; Kazem Mousavizadeh
Journal:  Rep Biochem Mol Biol       Date:  2015-10

4.  Genetic association study of age-related macular degeneration in the Spanish population.

Authors:  María Brión; Manuel Sanchez-Salorio; Marta Cortón; Maria de la Fuente; Belen Pazos; Mohammad Othman; Anand Swaroop; Goncalo Abecasis; Beatriz Sobrino; Angel Carracedo
Journal:  Acta Ophthalmol       Date:  2010-11-25       Impact factor: 3.761

5.  Age-related macular degeneration: current treatment and future options.

Authors:  Tanya Moutray; Usha Chakravarthy
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

6.  Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Authors:  Henry F Edelhauser; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

7.  Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium.

Authors:  Bobbie Ann Austin; Baoying Liu; Zhuqing Li; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

8.  Regulatory regions of the paraoxonase 1 (PON1) gene are associated with neovascular age-related macular degeneration (AMD).

Authors:  Jadwiga Oczos; Christian Grimm; Daniel Barthelmes; Florian Sutter; Moreno Menghini; Barbara Kloeckener-Gruissem; Wolfgang Berger
Journal:  Age (Dordr)       Date:  2012-09-07

9.  Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype.

Authors:  Reecha Sofat; Juan P Casas; Andrew R Webster; Alan C Bird; Samantha S Mann; John R W Yates; Anthony T Moore; Tiina Sepp; Valentina Cipriani; Catey Bunce; Jane C Khan; Humma Shahid; Anand Swaroop; Gonçalo Abecasis; Kari E H Branham; Sepideh Zareparsi; Arthur A Bergen; Caroline C W Klaver; Dominique C Baas; Kang Zhang; Yuhong Chen; Daniel Gibbs; Bernhard H F Weber; Claudia N Keilhauer; Lars G Fritsche; Andrew Lotery; Angela J Cree; Helen L Griffiths; Shomi S Bhattacharya; Li L Chen; Sharon A Jenkins; Tunde Peto; Mark Lathrop; Thierry Leveillard; Michael B Gorin; Daniel E Weeks; Maria Carolina Ortube; Robert E Ferrell; Johanna Jakobsdottir; Yvette P Conley; Mati Rahu; Johan H Seland; Gisele Soubrane; Fotis Topouzis; Jesus Vioque; Laura Tomazzoli; Ian Young; John Whittaker; Usha Chakravarthy; Paulus T V M de Jong; Liam Smeeth; Astrid Fletcher; Aroon D Hingorani
Journal:  Int J Epidemiol       Date:  2012-01-13       Impact factor: 7.196

10.  Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration.

Authors:  Anna-Maija Tolppanen; Tanja Nevalainen; Marjukka Kolehmainen; Sanna Seitsonen; Ilkka Immonen; Matti Uusitupa; Kai Kaarniranta; Leena Pulkkinen
Journal:  Mol Vis       Date:  2009-04-15       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.